1. Immunology/Inflammation
    Metabolic Enzyme/Protease
  2. COX
    NO Synthase
    Cytochrome P450

Ginsenoside C-K (Synonyms: Ginsenoside K; Ginsenoside compound K)

Cat. No.: HY-N0904 Purity: 98.06%
Handling Instructions

Ginsenoside C-K, a bacterial metabolite of G-Rb1, exhibits anti-inflammatory effects by reducing iNOS and COX-2. Ginsenoside C-K exhibits an inhibition against the activity of CYP2C9 and CYP2A6 in human liver microsomes with IC50s of 32.0±3.6 μM and 63.6±4.2 μM, respectively.

For research use only. We do not sell to patients.

Ginsenoside C-K Chemical Structure

Ginsenoside C-K Chemical Structure

CAS No. : 39262-14-1

Size Price Stock Quantity
10 mM * 1 mL in DMSO USD 148 In-stock
Stock in Sweden
Estimated Time of Arrival: December 31
5 mg USD 108 In-stock
Stock in Sweden
Estimated Time of Arrival: December 31
10 mg USD 180 In-stock
Stock in Sweden
Estimated Time of Arrival: December 31
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

Ginsenoside C-K, a bacterial metabolite of G-Rb1, exhibits anti-inflammatory effects by reducing iNOS and COX-2. Ginsenoside C-K exhibits an inhibition against the activity of CYP2C9 and CYP2A6 in human liver microsomes with IC50s of 32.0±3.6 μM and 63.6±4.2 μM, respectively.

IC50 & Target[1][4]

COX-2

 

iNOS

 

CYP2C9

32 μM (IC50)

CYP2A6

63.6 μM (IC50)

In Vitro

Ginsenoside C-K, a bacterial metabolite of G-Rb1, exhibits anti-inflammatory effects mainly by reducing inducible nitric oxide synthase (iNOS), cyclooxygenase (COX)-2, and proinflammatory cytokines. Ginsenoside C-K suppresses the expression of proinflammatory cytokines by downregulating the activities of IRAK-1, MAPKs, IKK-α, and NF-κB in LPS-treated murine peritoneal macrophages. Ginsenoside C-K also suppresses the expression of iNOS and COX-2 by inhibiting NF-κB signaling in LPS-stimulated RAW264.7 cells. In zymosan-treated bone-marrow-derived macrophages (BMDMs) and RAW264.7 cells, Ginsenoside C-K inhibits inflammatory responses by negatively regulating the secretion of proinflammatory cytokines, the activation of MAPKs, and the generation of ROS. In addition, anti-inflammatory activity of Ginsenoside C-K has been observed in LPS-stimulated microglial cells. Ginsenoside C-K hinders inflammatory responses by controlling both the generation of ROS and the activities of MAPKs, NF-κB, and AP-1[1]. Ginsenoside C-K, a major metabolite of ginsenosides in the gastrointestinal tract, inhibits NF-κB signaling in a PXR-dependent manner. Ginsenoside C-K is shown to promote recovery of dextran sulfate sodium (DSS) -induced colitis by suppressing NF-κB activation. Ginsenoside C-K significantly reduces TNF-α-induced upregulation of IL-1β and iNOS mRNA levels, and restores the mRNA levels of PXR and CYP3A4 in LS174T cells[2]. Ginsenoside C-K, one of the intestinal metabolites of 20(S)-protopanaxadiol derivatives, exhibits an inhibition against the activity of CYP2C9 in human liver microsomes with an IC50 value of 32.0±3.6 μM, a weak inhibition against the activity of CYP2A6 in human liver microsomes with an IC50 value of 63.6±4.2 μM, and an even weaker inhibition against the activity of CYP2D6 in human liver microsomes with an IC50 value of more than 100 μM[4].

In Vivo

The weight of the collagen-induced arthritis (CIA) mice increases slowly and is significantly less than that of the normal DBA/1 mice beginning on d 3 after injection of the emulsion. Ginsenoside C-K (28, 56, and 112 mg/kg) mice recover their weight by d 32 after the emulsion injection. Ginsenoside C-K (56 and 112 mg/kg) and Methotrexate (MTX)-treated (2 mg/kg) mice show significantly increased body weight on d 50 as compared with CIA mice. Hind paw-swelling began on d 24 post-immunization. CIA mice are treated from d 28 to d 50. Arthritis scores are measured every 4 d beginning on d 24. Ginsenoside C-K (56 and 112 mg/kg) significantly reduces the arthritis scores of the mice on d 51[3].

References
Preparing Stock Solutions
Concentration Volume Mass 1 mg 5 mg 10 mg
1 mM 1.6055 mL 8.0274 mL 16.0547 mL
5 mM 0.3211 mL 1.6055 mL 3.2109 mL
10 mM 0.1605 mL 0.8027 mL 1.6055 mL
Please refer to the solubility information to select the appropriate solvent.
Cell Assay
[2]

LS174T cells are seeded in cell imaging dish. After overnight incubation, cells are treated with ginseng saponin extract (GSE) (100 μg/mL), Rb1 (10 μM), or Ginsenoside C-K (10 μM) for 3 hours, followed by an additional incubation with or without TNF-α (20 ng/mL) for 6 hours. At the end of the incubation, cells are harvested and fixed with 4% paraformaldehyde solution at 20°C for 20 minutes. After washing in PBS, cells are permeabilized with 0.2% Triton X-100 in PBS at room temperature for 5 minutes. After incubation in blocking buffer containing 0.1% Triton X-100 and 5% bovine serum albumin, cells are incubated with rabbit NF-κB p65 antibody at 4°C overnight and then with Alexa Fluor 488-conjugated anti-rabbit IgG antibody at room temperature for 30 minutes in 1% bovine serum albumin in PBS. Fluorescence photographs are obtained using a Zeiss 710 confocal microscope[2].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[3]

Mice[3]
Specific pathogen-free DBA/1 mice (male, 18±2 g) are used. DBA/1 mice are injected intradermally twice with 0.1 mL of this emulsion (containing 100 mg of chicken type II collagen (CII)/mouse) in the back and the base of the tail. The day of the first immunization is defined as d 0, and the booster injection is administered into the back on d 21. After the onset of arthritis, animals are randomly divided into five groups, and each experimental group consists of ten mice. Mice with CIA are intragastrically administered Ginsenoside C-K (28, 56, or 112 mg/kg) once per day or MTX (2 mg/kg) once every 3 d from d 28 to d 51 after immunization. Normal and CIA mice are administered an equal volume of vehicle (CMC-Na) at the same time[3].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References
Molecular Weight

622.87

Formula

C₃₆H₆₂O₈

CAS No.

39262-14-1

SMILES

C[[email protected]@]([[email protected]@]12C)(CC[[email protected]@]3([H])C4(C)C)[[email protected]@](C[[email protected]@H](O)[[email protected]]1([H])[[email protected]]([[email protected]@](CC/C=C(C)/C)(C)O[[email protected]@H]([[email protected]@H]([[email protected]@H](O)[[email protected]@H]5O)O)O[[email protected]@H]5CO)([H])CC2)([H])[[email protected]]3(CC[[email protected]@H]4O)C

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

10 mM in DMSO

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number *

 

Organization name *

Country or Region *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Ginsenoside C-K
Cat. No.:
HY-N0904
Quantity: